Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:NMDA receptor agonist
go back to main search page
Accession:CHEBI:64571 term browser browse the term
Definition:An excitatory amino acid agonist which binds to NMDA receptors and triggers a response.
Synonyms:related_synonym: N-methyl-D-aspartate receptor agonist;   N-methyl-D-aspartate receptor agonists;   NMDA receptor agonists;   NMDAR agonist;   NMDAR agonists


show annotations for term's descendants           Sort by:
 
[N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GNAT3 G protein subunit alpha transducin 3 affects response to substance ISO GNAT3 protein affects the susceptibility to NC 174 CTD PMID:16740645 NCBI chr 7:80,457,291...80,512,503
Ensembl chr 7:80,458,635...80,512,064
JBrowse link
creatine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCC9 ATP binding cassette subfamily C member 9 multiple interactions ISO Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] CTD PMID:11390963 NCBI chr12:21,797,389...21,941,863
Ensembl chr12:21,797,401...21,942,529
Ensembl chr12:21,797,401...21,942,529
JBrowse link
G APP amyloid beta precursor protein increases secretion EXP Creatine analog results in increased secretion of APP protein modified form CTD PMID:22906069 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
JBrowse link
G BDNF brain derived neurotrophic factor multiple interactions
increases expression
ISO Sirolimus inhibits the reaction [Creatine results in increased expression of BDNF protein] CTD PMID:33022268 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
JBrowse link
G CASP3 caspase 3 multiple interactions ISO [Creatine co-treated with Ribose] results in decreased activity of CASP3 protein CTD PMID:21220914 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G COL2A1 collagen type II alpha 1 chain multiple interactions ISO [COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine] CTD PMID:24709313 NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
JBrowse link
G CSF3 colony stimulating factor 3 multiple interactions EXP [CSF3 protein co-treated with Paclitaxel] results in decreased abundance of Creatine CTD PMID:9018096 NCBI chr17:40,015,440...40,017,813
Ensembl chr17:40,015,361...40,017,813
JBrowse link
G DEK DEK proto-oncogene increases chemical synthesis EXP DEK protein results in increased chemical synthesis of Creatine CTD PMID:28558019 NCBI chr 6:18,223,860...18,264,541
Ensembl chr 6:18,223,860...18,264,548
JBrowse link
G GATM glycine amidinotransferase increases chemical synthesis EXP GATM protein results in increased chemical synthesis of Creatine CTD PMID:16820567 NCBI chr15:45,361,124...45,402,227
Ensembl chr15:45,361,124...45,402,327
JBrowse link
G KCNJ11 potassium inwardly rectifying channel subfamily J member 11 multiple interactions ISO Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] CTD PMID:11390963 NCBI chr11:17,385,246...17,389,346
Ensembl chr11:17,385,859...17,389,331
Ensembl chr11:17,385,859...17,389,331
JBrowse link
G MTOR mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Creatine results in increased phosphorylation of MTOR protein
Sirolimus inhibits the reaction [Creatine results in increased phosphorylation of MTOR protein]
CTD PMID:33022268 NCBI chr 1:11,106,535...11,273,497
Ensembl chr 1:11,106,535...11,262,551
JBrowse link
G PPARGC1A PPARG coactivator 1 alpha increases expression EXP Creatine results in increased expression of PPARGC1A mRNA CTD PMID:23056435 NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
JBrowse link
G SNCA synuclein alpha multiple interactions ISO [coenzyme Q10 co-treated with Creatine] results in decreased expression of SNCA protein CTD PMID:19476553 NCBI chr 4:89,724,099...89,838,324
Ensembl chr 4:89,700,345...89,838,315
Ensembl chr 4:89,700,345...89,838,315
JBrowse link
creatinine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ARNTL aryl hydrocarbon receptor nuclear translocator like increases abundance ISO ARNTL gene mutant form results in increased abundance of Creatinine CTD PMID:27056296 NCBI chr11:13,276,552...13,387,268
Ensembl chr11:13,276,652...13,387,266
JBrowse link
G COL2A1 collagen type II alpha 1 chain multiple interactions ISO [COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine] CTD PMID:24709313 NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of Creatinine
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Creatinine]
CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,504
Ensembl chr15:90,083,045...90,102,504
JBrowse link
G LEPR leptin receptor affects abundance
multiple interactions
increases abundance
ISO LEPR affects the abundance of Creatinine
Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Creatinine]
CTD PMID:20567778 PMID:29988851 NCBI chr 1:65,420,652...65,641,559
Ensembl chr 1:65,420,652...65,641,559
JBrowse link
G NFE2L2 nuclear factor, erythroid 2 like 2 multiple interactions ISO [NFE2L2 protein affects the susceptibility to ochratoxin A] which results in increased abundance of Creatinine CTD PMID:28710020 NCBI chr 2:177,230,303...177,265,131
Ensembl chr 2:177,227,595...177,392,697
JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 multiple interactions ISO [SC 560 results in decreased activity of PTGS1 protein] which results in increased abundance of Creatinine CTD PMID:19629487 NCBI chr 9:122,369,906...122,395,703
Ensembl chr 9:122,370,530...122,395,703
JBrowse link
G SLC47A1 solute carrier family 47 member 1 multiple interactions EXP Creatinine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034
JBrowse link
G SLC47A2 solute carrier family 47 member 2 multiple interactions EXP Creatinine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr17:19,678,313...19,719,598
Ensembl chr17:19,678,288...19,718,979
JBrowse link
G SOD2 superoxide dismutase 2 decreases abundance EXP SOD2 protein results in decreased abundance of Creatinine CTD PMID:19917352 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
D-cycloserine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein] CTD PMID:24264887 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G EGR1 early growth response 1 increases expression ISO Cycloserine results in increased expression of EGR1 protein CTD PMID:19144966 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
JBrowse link
G FOS Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA] CTD PMID:12464447 NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230
JBrowse link
G HOMER1 homer scaffold protein 1 multiple interactions ISO Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA] CTD PMID:12464447 NCBI chr 5:79,372,636...79,514,134
Ensembl chr 5:79,372,636...79,514,134
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions ISO Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein] CTD PMID:11903061 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions ISO Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein] CTD PMID:11903061 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein] CTD PMID:24264887 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
glycine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADIPOQ adiponectin, C1Q and collagen domain containing increases expression ISO Glycine results in increased expression of ADIPOQ protein CTD PMID:18930730 NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
JBrowse link
G CLDN5 claudin 5 decreases expression EXP Glycine results in decreased expression of CLDN5 protein CTD PMID:30605748 NCBI chr22:19,523,024...19,525,337
Ensembl chr22:19,523,024...19,527,545
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP Glycine inhibits the reaction [Homocysteine results in increased expression of DDIT3 mRNA]; Glycine inhibits the reaction [Homocysteine results in increased expression of DDIT3 protein] CTD PMID:27064126 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DEK DEK proto-oncogene multiple interactions EXP DEK protein results in decreased chemical synthesis of and results in increased uptake of Glycine CTD PMID:28558019 NCBI chr 6:18,223,860...18,264,541
Ensembl chr 6:18,223,860...18,264,548
JBrowse link
G GLRA1 glycine receptor alpha 1 affects response to substance
increases activity
multiple interactions
affects activity
EXP
ISO
GLRA1 protein mutant form affects the susceptibility to Glycine
Glycine results in increased activity of GLRA1 protein
Cocaine inhibits the reaction [Glycine results in increased activity of GLRA1 protein]; Dronabinol inhibits the reaction [Cocaine inhibits the reaction [Glycine results in increased activity of GLRA1 protein]]
7alpha,8beta-dihydroxydeepoxysarcophine affects the reaction [Glycine results in increased activity of GLRA1 protein]; Ivermectin affects the reaction [Glycine affects the activity of GLRA1 protein mutant form]; sarcophine inhibits the reaction [Glycine results in increased activity of GLRA1 protein]
CTD PMID:27958714 PMID:32209479 PMID:32702364 NCBI chr 5:151,822,513...151,924,851
Ensembl chr 5:151,822,513...151,924,842
Ensembl chr 5:151,822,513...151,924,842
JBrowse link
G GRIA1 glutamate ionotropic receptor AMPA type subunit 1 multiple interactions ISO Glycine results in increased expression of and results in increased phosphorylation of GRIA1 protein; HNRNPK mutant form inhibits the reaction [Glycine results in increased expression of and results in increased phosphorylation of GRIA1 protein] CTD PMID:24990929 NCBI chr 5:153,490,670...153,813,873
Ensembl chr 5:153,489,615...153,813,869
JBrowse link
G HNRNPK heterogeneous nuclear ribonucleoprotein K affects localization
increases expression
multiple interactions
ISO Glycine affects the localization of HNRNPK protein
Glycine results in increased expression of HNRNPK mRNA
Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Glycine results in increased expression of HNRNPK mRNA]; Glycine results in increased expression of and results in increased phosphorylation of HNRNPK protein; HNRNPK mutant form inhibits the reaction [Glycine results in increased expression of and results in increased phosphorylation of GRIA1 protein]; HNRNPK mutant form inhibits the reaction [Glycine results in increased phosphorylation of MAPK1 protein]; HNRNPK mutant form inhibits the reaction [Glycine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Glycine results in increased phosphorylation of HNRNPK protein]
CTD PMID:24990929 NCBI chr 9:83,968,083...83,980,630
Ensembl chr 9:83,968,083...83,980,616
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP Glycine inhibits the reaction [Homocysteine results in increased expression of HSPA5 mRNA] CTD PMID:27064126 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G IL6 interleukin 6 multiple interactions
decreases expression
ISO Glycine affects the reaction [Sodium Glutamate affects the expression of IL6 mRNA]; Glycine affects the reaction [Sodium Glutamate affects the expression of IL6 protein]; Glycine inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]
Glycine results in decreased expression of IL6 protein
CTD PMID:18930730 PMID:22732655 NCBI chr 7:22,725,889...22,732,002
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G INS insulin multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Glycine analog CTD PMID:26820058 NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,341
Ensembl chr11:2,159,779...2,161,341
JBrowse link
G LEP leptin multiple interactions ISO Glycine affects the reaction [Sodium Glutamate affects the expression of LEP protein] CTD PMID:18930730 NCBI chr 7:128,241,201...128,257,629
Ensembl chr 7:128,241,278...128,257,629
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 multiple interactions
increases phosphorylation
ISO HNRNPK mutant form inhibits the reaction [Glycine results in increased phosphorylation of MAPK1 protein] CTD PMID:24990929 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation
multiple interactions
ISO Glycine results in increased phosphorylation of MAPK3 protein
HNRNPK mutant form inhibits the reaction [Glycine results in increased phosphorylation of MAPK3 protein]
CTD PMID:24990929 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G NFKBIA NFKB inhibitor alpha multiple interactions
increases degradation
ISO [Glycine co-treated with TNF protein] results in increased degradation of NFKBIA protein
Glycine results in increased degradation of NFKBIA protein
CTD PMID:22732655 NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,511...35,404,749
Ensembl chr14:35,401,511...35,404,749
JBrowse link
G NFKBIB NFKB inhibitor beta increases degradation ISO Glycine results in increased degradation of NFKBIB protein CTD PMID:22732655 NCBI chr19:38,899,503...38,908,894
Ensembl chr19:38,899,700...38,908,893
JBrowse link
G OCLN occludin decreases expression EXP Glycine results in decreased expression of OCLN protein CTD PMID:30605748 NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
JBrowse link
G OTC ornithine transcarbamylase affects metabolic processing
multiple interactions
ISO OTC gene mutant form affects the metabolism of Glycine
Sodium Benzoate affects the reaction [OTC gene mutant form affects the metabolism of Glycine]
CTD PMID:3091026 NCBI chr  X:38,352,528...38,421,446
Ensembl chr  X:38,352,586...38,421,446
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma increases expression ISO Glycine results in increased expression of PPARG mRNA CTD PMID:18930730 NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
JBrowse link
G RETN resistin multiple interactions ISO Glycine affects the reaction [Sodium Glutamate affects the expression of RETN protein] CTD PMID:18930730 NCBI chr19:7,669,049...7,670,455
Ensembl chr19:7,669,049...7,670,455
JBrowse link
G SLC2A1 solute carrier family 2 member 1 decreases expression EXP Glycine results in decreased expression of SLC2A1 protein CTD PMID:30605748 NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
Ensembl chr 1:42,925,353...42,958,893
JBrowse link
G TNF tumor necrosis factor multiple interactions
decreases expression
ISO [Glycine co-treated with TNF protein] results in increased degradation of NFKBIA protein; Glycine affects the reaction [Sodium Glutamate affects the expression of TNF mRNA]; Glycine inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Glycine inhibits the reaction [TNF protein results in increased expression of TNF mRNA]
Glycine results in decreased expression of TNF mRNA
CTD PMID:18930730 PMID:22732655 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G XBP1 X-box binding protein 1 multiple interactions EXP Glycine affects the reaction [Homocysteine results in increased splicing of XBP1 mRNA] CTD PMID:27064126 NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
JBrowse link
glycine betaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABI3BP ABI family member 3 binding protein increases expression ISO Betaine results in increased expression of ABI3BP mRNA CTD PMID:26391144 NCBI chr 3:100,749,156...100,993,508
Ensembl chr 3:100,749,156...100,993,515
JBrowse link
G ACACA acetyl-CoA carboxylase alpha multiple interactions ISO [Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA CTD PMID:22648174 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
JBrowse link
G ADSS2 adenylosuccinate synthase 2 decreases expression ISO Betaine results in decreased expression of ADSS mRNA CTD PMID:26391144 NCBI chr 1:244,408,494...244,452,060
Ensembl chr 1:244,408,494...244,451,909
JBrowse link
G AHCY adenosylhomocysteinase decreases expression ISO Betaine results in decreased expression of AHCY mRNA CTD PMID:22945834 PMID:26391144 NCBI chr20:34,235,012...34,311,976
Ensembl chr20:34,280,268...34,311,802
JBrowse link
G AKIP1 A-kinase interacting protein 1 increases expression ISO Betaine results in increased expression of AKIP1 mRNA CTD PMID:26391144 NCBI chr11:8,911,117...8,920,079
Ensembl chr11:8,911,139...8,920,084
JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B decreases expression ISO Betaine results in decreased expression of AKR1B1 mRNA CTD PMID:26391144 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284
JBrowse link
G ALDH2 aldehyde dehydrogenase 2 family member multiple interactions ISO [Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein CTD PMID:20118189 NCBI chr12:111,766,933...111,817,532
Ensembl chr12:111,766,887...111,817,532
JBrowse link
G APEX1 apurinic/apyrimidinic endodeoxyribonuclease 1 decreases expression ISO Betaine results in decreased expression of APEX1 mRNA CTD PMID:26391144 NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
JBrowse link
G APP amyloid beta precursor protein multiple interactions ISO Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein] CTD PMID:19635394 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
JBrowse link
G ATP7B ATPase copper transporting beta multiple interactions ISO ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] CTD PMID:22945834 NCBI chr13:51,932,669...52,012,130
Ensembl chr13:51,930,436...52,012,125
JBrowse link
G AXIN1 axin 1 multiple interactions ISO [Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene CTD PMID:16868943 NCBI chr16:287,440...355,226
Ensembl chr16:287,440...352,723
JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression ISO Betaine results in decreased expression of BAX protein CTD PMID:25080425 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator affects binding
increases expression
EXP
ISO
Betaine analog binds to BCL2 protein
Betaine results in increased expression of BCL2 protein
CTD PMID:25080425 PMID:25765238 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BHLHE40 basic helix-loop-helix family member e40 increases expression ISO Betaine results in increased expression of BHLHE40 mRNA CTD PMID:26391144 NCBI chr 3:4,979,420...4,985,323
Ensembl chr 3:4,979,437...4,985,323
JBrowse link
G BHMT betaine--homocysteine S-methyltransferase increases metabolic processing EXP BHMT protein results in increased metabolism of Betaine CTD PMID:18230605 NCBI chr 5:79,111,809...79,132,288
Ensembl chr 5:79,111,809...79,132,288
JBrowse link
G BRF1 BRF1 RNA polymerase III transcription initiation factor subunit multiple interactions EXP Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein] CTD PMID:32418914 NCBI chr14:105,209,286...105,315,589
Ensembl chr14:105,209,286...105,315,589
JBrowse link
G CAB39L calcium binding protein 39 like decreases expression ISO Betaine results in decreased expression of CAB39L mRNA CTD PMID:26391144 NCBI chr13:49,308,650...49,444,851
Ensembl chr13:49,308,650...49,444,064
JBrowse link
G CASP1 caspase 1 increases expression ISO Betaine results in increased expression of CASP1 mRNA CTD PMID:26391144 NCBI chr11:105,025,443...105,035,591
Ensembl chr11:105,025,443...105,035,250
JBrowse link
G CASP3 caspase 3 multiple interactions ISO Betaine inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein] CTD PMID:24632105 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CAT catalase multiple interactions ISO [Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein
Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]
CTD PMID:12893363 PMID:20118189 PMID:24632105 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CCDC113 coiled-coil domain containing 113 increases expression ISO Betaine results in increased expression of CCDC113 mRNA CTD PMID:26391144 NCBI chr16:58,196,862...58,283,836
Ensembl chr16:58,231,157...58,283,836
JBrowse link
G CCL2 C-C motif chemokine ligand 2 multiple interactions ISO [Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA CTD PMID:22648174 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,218...34,257,203
JBrowse link
G CCL23 C-C motif chemokine ligand 23 increases expression ISO Betaine results in increased expression of CCL6 mRNA CTD PMID:26391144 NCBI chr17:36,013,056...36,018,179
Ensembl chr17:36,013,056...36,017,972
JBrowse link
G CCL5 C-C motif chemokine ligand 5 increases expression ISO Betaine results in increased expression of CCL5 mRNA CTD PMID:26391144 NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
JBrowse link
G CCNB2 cyclin B2 decreases expression ISO Betaine results in decreased expression of CCNB2 mRNA CTD PMID:26391144 NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045
JBrowse link
G CD44 CD44 molecule (Indian blood group) decreases expression ISO Betaine results in decreased expression of CD44 mRNA CTD PMID:26391144 NCBI chr11:35,139,168...35,232,402
Ensembl chr11:35,138,882...35,232,402
Ensembl chr11:35,138,882...35,232,402
JBrowse link
G CDC42EP2 CDC42 effector protein 2 decreases expression ISO Betaine results in decreased expression of CDC42EP2 mRNA CTD PMID:26391144 NCBI chr11:65,314,866...65,322,417
Ensembl chr11:65,314,866...65,322,417
JBrowse link
G CDH13 cadherin 13 decreases expression ISO Betaine results in decreased expression of CDH13 mRNA CTD PMID:26391144 NCBI chr16:82,626,823...83,800,640
Ensembl chr16:82,626,965...83,800,640
JBrowse link
G CDKN2A cyclin dependent kinase inhibitor 2A multiple interactions ISO Betaine promotes the reaction [Diethylnitrosamine results in decreased expression of CDKN2A mRNA] CTD PMID:19642983 NCBI chr 9:21,967,752...21,995,324
Ensembl chr 9:21,967,753...21,995,301
Ensembl chr 9:21,967,753...21,995,301
JBrowse link
G CES3 carboxylesterase 3 increases expression ISO Betaine results in increased expression of CES3 mRNA CTD PMID:26391144 NCBI chr16:66,961,266...66,975,149
Ensembl chr16:66,961,245...66,975,149
JBrowse link
G CKB creatine kinase B increases expression ISO Betaine results in increased expression of CKB mRNA CTD PMID:26391144 NCBI chr14:103,519,667...103,522,833
Ensembl chr14:103,519,667...103,522,833
JBrowse link
G CKS1B CDC28 protein kinase regulatory subunit 1B decreases expression ISO Betaine results in decreased expression of CKS1B mRNA CTD PMID:26391144 NCBI chr 1:154,974,681...154,979,251
Ensembl chr 1:154,974,653...154,979,251
JBrowse link
G COTL1 coactosin like F-actin binding protein 1 decreases expression ISO Betaine results in decreased expression of COTL1 mRNA CTD PMID:26391144 NCBI chr16:84,565,596...84,618,078
Ensembl chr16:84,565,596...84,618,078
JBrowse link
G CPT1A carnitine palmitoyltransferase 1A multiple interactions
decreases expression
ISO Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in decreased expression of CPT1A mRNA
CTD PMID:22945834 NCBI chr11:68,754,620...68,844,410
Ensembl chr11:68,754,620...68,844,410
JBrowse link
G CXCL16 C-X-C motif chemokine ligand 16 decreases expression ISO Betaine results in decreased expression of CXCL16 mRNA CTD PMID:26391144 NCBI chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
Ensembl chr17:4,733,533...4,739,928
JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions ISO
EXP
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]
Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1]
CTD PMID:20118189 PMID:21352821 NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
JBrowse link
G CYP4Z1 cytochrome P450 family 4 subfamily Z member 1 multiple interactions ISO [Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of CYP4A10 protein CTD PMID:20118189 NCBI chr 1:47,055,525...47,118,320
Ensembl chr 1:47,067,231...47,118,318
JBrowse link
G CYSLTR1 cysteinyl leukotriene receptor 1 increases expression ISO Betaine results in increased expression of CYSLTR1 mRNA CTD PMID:26391144 NCBI chr  X:78,271,468...78,327,611
Ensembl chr  X:78,271,468...78,327,691
JBrowse link
G DAPK1 death associated protein kinase 1 decreases expression ISO Betaine results in decreased expression of DAPK1 mRNA CTD PMID:26391144 NCBI chr 9:87,497,228...87,708,634
Ensembl chr 9:87,497,228...87,708,634
JBrowse link
G DLX2 distal-less homeobox 2 increases expression ISO Betaine results in increased expression of DLX2 mRNA CTD PMID:26391144 NCBI chr 2:172,099,438...172,102,900
Ensembl chr 2:172,099,438...172,102,900
JBrowse link
G DNMT1 DNA methyltransferase 1 multiple interactions
increases expression
ISO Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA]
Betaine results in increased expression of DNMT1 mRNA
CTD PMID:22945834 NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,345...10,231,286
Ensembl chr19:10,133,345...10,231,286
JBrowse link
G DNMT3B DNA methyltransferase 3 beta decreases expression ISO Betaine results in decreased expression of DNMT3B mRNA CTD PMID:22945834 NCBI chr20:32,762,385...32,809,356
Ensembl chr20:32,762,385...32,809,356
JBrowse link
G ECT2 epithelial cell transforming 2 decreases expression ISO Betaine results in decreased expression of ECT2 mRNA CTD PMID:26391144 NCBI chr 3:172,750,694...172,829,273
Ensembl chr 3:172,750,682...172,821,474
JBrowse link
G EEF2K eukaryotic elongation factor 2 kinase increases expression ISO Betaine results in increased expression of EEF2K mRNA CTD PMID:26391144 NCBI chr16:22,206,278...22,288,738
Ensembl chr16:22,206,278...22,288,738
JBrowse link
G EGR1 early growth response 1 increases expression ISO Betaine results in increased expression of EGR1 mRNA CTD PMID:26391144 NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
JBrowse link
G ELF3 E74 like ETS transcription factor 3 decreases expression ISO Betaine results in decreased expression of ELF3 mRNA CTD PMID:26391144 NCBI chr 1:202,010,583...202,017,183
Ensembl chr 1:202,007,945...202,017,183
JBrowse link
G EMC9 ER membrane protein complex subunit 9 increases expression ISO Betaine results in increased expression of EMC9 mRNA CTD PMID:26391144 NCBI chr14:24,138,959...24,142,602
Ensembl chr14:24,138,959...24,141,591
JBrowse link
G EPHB6 EPH receptor B6 increases expression ISO Betaine results in increased expression of EPHB6 mRNA CTD PMID:26391144 NCBI chr 7:142,854,639...142,871,093
Ensembl chr 7:142,855,061...142,871,094
JBrowse link
G F8 coagulation factor VIII multiple interactions
increases secretion
EXP Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form
Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form
CTD PMID:22973456 NCBI chr  X:154,835,792...155,022,723
Ensembl chr  X:154,835,788...155,026,940
JBrowse link
G F9 coagulation factor IX increases secretion EXP Betaine results in increased secretion of F9 protein CTD PMID:22973456 NCBI chr  X:139,530,720...139,563,459
Ensembl chr  X:139,530,739...139,563,459
Ensembl chr  X:139,530,739...139,563,459
JBrowse link
G FASN fatty acid synthase multiple interactions ISO [Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] CTD PMID:22648174 NCBI chr17:82,078,338...82,098,303
Ensembl chr17:82,078,338...82,098,294
JBrowse link
G FLRT3 fibronectin leucine rich transmembrane protein 3 increases expression ISO Betaine results in increased expression of FLRT3 mRNA CTD PMID:26391144 NCBI chr20:14,322,985...14,337,847
Ensembl chr20:14,322,985...14,337,614
JBrowse link
G FXYD2 FXYD domain containing ion transport regulator 2 decreases expression ISO Betaine results in decreased expression of FXYD2 mRNA; Betaine results in decreased expression of FXYD2 mRNA alternative form CTD PMID:26391144 NCBI chr11:117,820,057...117,828,089
Ensembl chr11:117,800,844...117,828,698
JBrowse link
G GAL galanin and GMAP prepropeptide multiple interactions ISO Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:19294532 NCBI chr11:68,684,544...68,691,175
Ensembl chr11:68,683,779...68,691,175
JBrowse link
G GPCPD1 glycerophosphocholine phosphodiesterase 1 increases expression ISO Betaine results in increased expression of GPCPD1 mRNA CTD PMID:26391144 NCBI chr20:5,544,439...5,611,046
Ensembl chr20:5,544,439...5,611,006
Ensembl chr20:5,544,439...5,611,006
JBrowse link
G GUSB glucuronidase beta multiple interactions ISO Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:19294532 NCBI chr 7:65,960,684...65,982,230
Ensembl chr 7:65,960,684...65,982,215
JBrowse link
G H2AZ1 H2A.Z variant histone 1 decreases expression ISO Betaine results in decreased expression of H2AZ1 mRNA CTD PMID:26391144 NCBI chr 4:99,948,088...99,950,275
Ensembl chr 4:99,948,086...99,950,355
JBrowse link
G HIP1 huntingtin interacting protein 1 decreases expression ISO Betaine results in decreased expression of HIP1 mRNA CTD PMID:26391144 NCBI chr 7:75,533,298...75,738,976
Ensembl chr 7:75,533,298...75,738,962
JBrowse link
G HMGB2 high mobility group box 2 decreases expression ISO Betaine results in decreased expression of HMGB2 mRNA CTD PMID:26391144 NCBI chr 4:173,331,376...173,334,358
Ensembl chr 4:173,331,376...173,334,432
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 decreases expression ISO Betaine results in decreased expression of HSPA5 mRNA CTD PMID:22945834 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G ID2 inhibitor of DNA binding 2 increases expression ISO Betaine results in increased expression of ID2 mRNA CTD PMID:26391144 NCBI chr 2:8,682,056...8,684,461
Ensembl chr 2:8,678,845...8,684,461
JBrowse link
G IDH2 isocitrate dehydrogenase (NADP(+)) 2 multiple interactions
increases abundance
ISO Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine] CTD PMID:27469509 NCBI chr15:90,083,045...90,102,468
Ensembl chr15:90,083,045...90,102,504
Ensembl chr15:90,083,045...90,102,504
JBrowse link
G IRX4 iroquois homeobox 4 decreases expression ISO Betaine results in decreased expression of IRX4 mRNA CTD PMID:26391144 NCBI chr 5:1,877,413...1,887,179
Ensembl chr 5:1,877,413...1,887,236
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit increases expression ISO Betaine results in increased expression of JUN mRNA CTD PMID:26391144 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G KHDRBS3 KH RNA binding domain containing, signal transduction associated 3 decreases expression ISO Betaine results in decreased expression of KHDRBS3 mRNA CTD PMID:26391144 NCBI chr 8:135,457,456...135,656,516
Ensembl chr 8:135,457,456...135,656,722
JBrowse link
G KIF1B kinesin family member 1B increases expression ISO Betaine results in increased expression of KIF1B mRNA CTD PMID:26391144 NCBI chr 1:10,210,570...10,381,603
Ensembl chr 1:10,210,570...10,381,603
Ensembl chr 1:10,210,570...10,381,603
JBrowse link
G KIF22 kinesin family member 22 decreases expression ISO Betaine results in decreased expression of KIF22 mRNA CTD PMID:26391144 NCBI chr16:29,790,734...29,805,543
Ensembl chr16:29,790,719...29,805,385
Ensembl chr16:29,790,719...29,805,385
JBrowse link
G KLF10 Kruppel like factor 10 increases expression ISO Betaine results in increased expression of KLF10 mRNA CTD PMID:26391144 NCBI chr 8:102,648,784...102,655,725
Ensembl chr 8:102,648,784...102,655,725
JBrowse link
G KRT2 keratin 2 increases expression ISO Betaine results in increased expression of KRT2 mRNA; Betaine results in increased expression of KRT2 protein CTD PMID:26391144 NCBI chr12:52,644,558...52,652,211
Ensembl chr12:52,644,558...52,652,211
JBrowse link
G LARS1 leucyl-tRNA synthetase 1 decreases expression ISO Betaine results in decreased expression of LARS mRNA CTD PMID:26391144 NCBI chr 5:146,113,034...146,182,731
Ensembl chr 5:146,113,034...146,182,650
Ensembl chr 5:146,113,034...146,182,650
JBrowse link
G LIN9 lin-9 DREAM MuvB core complex component decreases expression ISO Betaine results in decreased expression of LIN9 mRNA CTD PMID:26391144 NCBI chr 1:226,231,149...226,310,082
Ensembl chr 1:226,231,149...226,309,869
JBrowse link
G MARCHF6 membrane associated ring-CH-type finger 6 multiple interactions
decreases stability
EXP Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein] CTD PMID:30545937 NCBI chr 5:10,353,693...10,440,388
Ensembl chr 5:10,353,695...10,440,388
JBrowse link
G MCM3 minichromosome maintenance complex component 3 decreases expression ISO Betaine results in decreased expression of MCM3 mRNA CTD PMID:26391144 NCBI chr 6:52,264,015...52,284,742
Ensembl chr 6:52,264,014...52,284,881
JBrowse link
G MCM4 minichromosome maintenance complex component 4 decreases expression ISO Betaine results in decreased expression of MCM4 mRNA CTD PMID:26391144 NCBI chr 8:47,960,941...47,978,160
Ensembl chr 8:47,960,185...47,978,160
JBrowse link
G MCM7 minichromosome maintenance complex component 7 decreases expression ISO Betaine results in decreased expression of MCM7 mRNA CTD PMID:26391144 NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,728...100,101,940
JBrowse link
G MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1 like decreases expression ISO Betaine results in decreased expression of MTHFD1L mRNA CTD PMID:26391144 NCBI chr 6:150,865,684...151,101,887
Ensembl chr 6:150,865,549...151,101,887
Ensembl chr 6:150,865,549...151,101,887
JBrowse link
G MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase decreases expression ISO Betaine results in decreased expression of MTHFD2 mRNA CTD PMID:26391144 NCBI chr 2:74,198,591...74,217,565
Ensembl chr 2:74,198,610...74,217,565
Ensembl chr 2:74,198,610...74,217,565
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Betaine inhibits the reaction [Diethylnitrosamine results in increased expression of MYC mRNA] CTD PMID:19642983 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G NBL1 NBL1, DAN family BMP antagonist increases expression ISO Betaine results in increased expression of NBL1 mRNA CTD PMID:26391144 NCBI chr 1:19,643,229...19,658,452
Ensembl chr 1:19,596,979...19,658,456
JBrowse link
G NCKIPSD NCK interacting protein with SH3 domain decreases expression ISO Betaine results in decreased expression of NCKIPSD mRNA CTD PMID:26391144 NCBI chr 3:48,663,814...48,685,941
Ensembl chr 3:48,673,844...48,686,364
JBrowse link
G NDRG4 NDRG family member 4 decreases expression ISO Betaine results in decreased expression of NDRG4 mRNA CTD PMID:26391144 NCBI chr16:58,463,704...58,515,403
Ensembl chr16:58,462,846...58,513,628
JBrowse link
G NUPR1 nuclear protein 1, transcriptional regulator decreases expression ISO Betaine results in decreased expression of NUPR1 mRNA CTD PMID:26391144 NCBI chr16:28,532,708...28,538,974
Ensembl chr16:28,532,708...28,539,174
Ensembl chr16:28,532,708...28,539,174
JBrowse link
G OGG1 8-oxoguanine DNA glycosylase multiple interactions ISO Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter] CTD PMID:22064374 NCBI chr 3:9,749,952...9,788,246
Ensembl chr 3:9,749,944...9,788,219
JBrowse link
G PCP4 Purkinje cell protein 4 increases expression ISO Betaine results in increased expression of PCP4 mRNA CTD PMID:26391144 NCBI chr21:39,867,438...39,929,392
Ensembl chr21:39,867,438...39,929,397
JBrowse link
G PCTP phosphatidylcholine transfer protein decreases expression ISO Betaine results in decreased expression of PCTP mRNA CTD PMID:26391144 NCBI chr17:55,750,979...55,845,001
Ensembl chr17:55,751,051...55,842,830
JBrowse link
G POLA2 DNA polymerase alpha 2, accessory subunit decreases expression ISO Betaine results in decreased expression of POLA2 mRNA CTD PMID:26391144 NCBI chr11:65,261,917...65,306,269
Ensembl chr11:65,261,920...65,305,589
Ensembl chr11:65,261,920...65,305,589
JBrowse link
G POLE2 DNA polymerase epsilon 2, accessory subunit decreases expression ISO Betaine results in decreased expression of POLE2 mRNA CTD PMID:26391144 NCBI chr14:49,643,555...49,688,417
Ensembl chr14:49,643,555...49,688,422
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha multiple interactions
decreases expression
ISO [Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein
Betaine results in decreased expression of PPARA mRNA
CTD PMID:20118189 PMID:22945834 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,756
JBrowse link
G PRSS23 serine protease 23 increases expression ISO Betaine results in increased expression of PRSS23 mRNA CTD PMID:26391144 NCBI chr11:86,791,071...86,952,910
Ensembl chr11:86,791,059...86,952,910
JBrowse link
G PSEN1 presenilin 1 multiple interactions ISO Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter] CTD PMID:19635394 NCBI chr14:73,136,436...73,223,691
Ensembl chr14:73,136,418...73,223,691
JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases expression ISO Betaine results in decreased expression of PTGS1 mRNA CTD PMID:26391144 NCBI chr 9:122,369,906...122,395,703
Ensembl chr 9:122,370,530...122,395,703
JBrowse link
G RANBP3L RAN binding protein 3 like decreases expression ISO Betaine results in decreased expression of RANBP3L mRNA CTD PMID:26391144 NCBI chr 5:36,246,913...36,301,902
Ensembl chr 5:36,246,913...36,302,114
Ensembl chr 5:36,246,913...36,302,114
JBrowse link
G RELA RELA proto-oncogene, NF-kB subunit multiple interactions ISO Betaine inhibits the reaction [Fructose results in decreased activity of RELA protein] CTD PMID:25559852 NCBI chr11:65,653,601...65,662,946
Ensembl chr11:65,653,597...65,663,090
JBrowse link
G RGS2 regulator of G protein signaling 2 increases expression ISO Betaine results in increased expression of RGS2 mRNA CTD PMID:26391144 NCBI chr 1:192,809,039...192,812,275
Ensembl chr 1:192,809,039...192,812,275
JBrowse link
G RRM2 ribonucleotide reductase regulatory subunit M2 decreases expression ISO Betaine results in decreased expression of RRM2 mRNA CTD PMID:26391144 NCBI chr 2:10,122,568...10,211,010
Ensembl chr 2:10,120,698...10,211,725
JBrowse link
G SCD stearoyl-CoA desaturase decreases expression ISO Betaine results in decreased expression of SCD1 mRNA CTD PMID:26391144 NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
JBrowse link
G SECTM1 secreted and transmembrane 1 increases expression ISO Betaine results in increased expression of SECTM1A mRNA CTD PMID:26391144 NCBI chr17:82,321,024...82,333,951
Ensembl chr17:82,321,024...82,334,074
JBrowse link
G SERINC2 serine incorporator 2 decreases expression ISO Betaine results in decreased expression of SERINC2 mRNA CTD PMID:26391144 NCBI chr 1:31,409,777...31,434,678
Ensembl chr 1:31,409,565...31,434,680
JBrowse link
G SLC16A6 solute carrier family 16 member 6 increases expression ISO Betaine results in increased expression of SLC16A6 mRNA CTD PMID:26391144 NCBI chr17:68,267,026...68,291,439
Ensembl chr17:68,267,026...68,291,267
JBrowse link
G SLC22A5 solute carrier family 22 member 5 multiple interactions EXP Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] CTD PMID:16928358 NCBI chr 5:132,369,704...132,395,614
Ensembl chr 5:132,369,752...132,395,614
Ensembl chr 5:132,369,752...132,395,614
JBrowse link
G SLC36A1 solute carrier family 36 member 1 increases uptake ISO SLC36A1 protein results in increased uptake of Betaine CTD PMID:18845132 NCBI chr 5:151,411,344...151,556,318
Ensembl chr 5:151,437,046...151,492,379
JBrowse link
G SLC6A12 solute carrier family 6 member 12 multiple interactions ISO Betaine inhibits the reaction [Lipopolysaccharides results in increased expression of SLC6A12 mRNA] CTD PMID:22053950 NCBI chr12:190,081...214,157
Ensembl chr12:190,077...214,570
JBrowse link
G SLC6A20 solute carrier family 6 member 20 increases uptake ISO SLC6A20B protein results in increased uptake of Betaine CTD PMID:18845132 NCBI chr 3:45,755,449...45,796,553
Ensembl chr 3:45,755,449...45,796,536
JBrowse link
G SLC6A9 solute carrier family 6 member 9 decreases expression ISO Betaine results in decreased expression of SLC6A9 mRNA CTD PMID:26391144 NCBI chr 1:43,996,483...44,031,462
Ensembl chr 1:43,991,500...44,031,467
JBrowse link
G SNX10 sorting nexin 10 decreases expression ISO Betaine results in decreased expression of SNX10 mRNA CTD PMID:26391144 NCBI chr 7:26,291,862...26,374,383
Ensembl chr 7:26,291,895...26,374,329
Ensembl chr 7:26,291,895...26,374,329
JBrowse link
G SOSTDC1 sclerostin domain containing 1 increases expression ISO Betaine results in increased expression of SOSTDC1 mRNA CTD PMID:26391144 NCBI chr 7:16,461,481...16,465,738
Ensembl chr 7:16,461,481...16,530,580
JBrowse link
G SPC25 SPC25 component of NDC80 kinetochore complex decreases expression ISO Betaine results in decreased expression of SPC25 mRNA CTD PMID:26391144 NCBI chr 2:168,865,045...168,890,443
Ensembl chr 2:168,834,132...168,913,371
JBrowse link
G SSR4 signal sequence receptor subunit 4 decreases expression ISO Betaine results in decreased expression of SSR4 mRNA CTD PMID:26391144 NCBI chr  X:153,794,159...153,798,512
Ensembl chr  X:153,793,516...153,798,499
JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions ISO Betaine promotes the reaction [Isoproterenol results in increased phosphorylation of STAT3 protein] CTD PMID:25080425 NCBI chr17:42,313,324...42,388,502
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
Ensembl chr17:42,313,324...42,388,482
JBrowse link
G STMN1 stathmin 1 decreases expression ISO Betaine results in decreased expression of STMN1 mRNA CTD PMID:26391144 NCBI chr 1:25,884,179...25,906,880
Ensembl chr 1:25,884,181...25,906,991
JBrowse link
G STXBP1 syntaxin binding protein 1 decreases expression ISO Betaine results in decreased expression of STXBP1 mRNA CTD PMID:26391144 NCBI chr 9:127,611,912...127,696,029
Ensembl chr 9:127,579,370...127,696,027
JBrowse link
G TGFB2 transforming growth factor beta 2 increases expression ISO Betaine results in increased expression of TGFB2 mRNA CTD PMID:26391144 NCBI chr 1:218,345,336...218,444,619
Ensembl chr 1:218,345,336...218,444,619
JBrowse link
G TNF tumor necrosis factor multiple interactions ISO Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA] CTD PMID:22945834 NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
JBrowse link
G TRIB2 tribbles pseudokinase 2 decreases expression ISO Betaine results in decreased expression of TRIB2 mRNA CTD PMID:26391144 NCBI chr 2:12,716,936...12,742,734
Ensembl chr 2:12,716,889...12,742,734
JBrowse link
G UPK3BL1 uroplakin 3B like 1 decreases expression ISO Betaine results in decreased expression of UPK3BL1 mRNA CTD PMID:26391144 NCBI chr 7:102,637,025...102,642,791
Ensembl chr 7:102,637,025...102,642,791
JBrowse link
G WNK4 WNK lysine deficient protein kinase 4 decreases expression ISO Betaine results in decreased expression of WNK4 mRNA CTD PMID:26391144 NCBI chr17:42,779,701...42,797,066
Ensembl chr17:42,780,610...42,797,066
JBrowse link
G YBX2 Y-box binding protein 2 decreases expression ISO Betaine results in decreased expression of YBX2 mRNA CTD PMID:26391144 NCBI chr17:7,288,254...7,294,639
Ensembl chr17:7,288,263...7,294,639
JBrowse link
glycochenodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AGT angiotensinogen multiple interactions
decreases response to substance
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] CTD PMID:23300732 NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,702,523...230,714,122
Ensembl chr 1:230,702,523...230,714,122
JBrowse link
G AGTR1 angiotensin II receptor type 1 multiple interactions ISO AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; AGTR1 protein promotes the reaction [AGT protein results in decreased susceptibility to Glycochenodeoxycholic Acid] CTD PMID:23300732 NCBI chr 3:148,697,903...148,743,003
Ensembl chr 3:148,697,784...148,743,008
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG5 autophagy related 5 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA; Glycochenodeoxycholic Acid results in decreased expression of ATG5 protein
TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]
CTD PMID:32439580 NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G ATP6V0D1 ATPase H+ transporting V0 subunit d1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V0D1 mRNA CTD PMID:32439580 NCBI chr16:67,438,019...67,481,157
Ensembl chr16:67,438,014...67,481,181
JBrowse link
G ATP6V1E1 ATPase H+ transporting V1 subunit E1 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of ATP6V1E1 mRNA CTD PMID:32439580 NCBI chr22:17,592,136...17,628,822
Ensembl chr22:17,592,136...17,628,749
JBrowse link
G BCL2A1 BCL2 related protein A1 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BCL2A1 mRNA CTD PMID:15767249 NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196
JBrowse link
G BCL2L13 BCL2 like 13 decreases expression EXP Glycochenodeoxycholic Acid results in decreased expression of BCL2L13 protein CTD PMID:32439580 NCBI chr22:17,628,855...17,730,855
Ensembl chr22:17,628,855...17,730,855
JBrowse link
G BECN1 beclin 1 multiple interactions
decreases expression
EXP TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]
Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA; Glycochenodeoxycholic Acid results in decreased expression of BECN1 protein
CTD PMID:32439580 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of BIRC5 mRNA CTD PMID:15767249 NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
JBrowse link
G CASP3 caspase 3 multiple interactions
increases cleavage
increases activity
EXP
ISO
Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Egtazic Acid promotes the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; [AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]; AGTR1 protein promotes the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; candesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; irbesartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; U 0126 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Valsartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]
CTD PMID:12873810 PMID:15767249 PMID:16322111 PMID:19837105 PMID:20020783 PMID:23300732 PMID:25125499 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CASP8 caspase 8 increases activity
increases cleavage
ISO Glycochenodeoxycholic Acid results in increased activity of CASP8 protein
Glycochenodeoxycholic Acid results in increased cleavage of CASP8 protein
CTD PMID:12873810 PMID:15767249 PMID:25125499 NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,287,711
JBrowse link
G CASP9 caspase 9 increases activity
multiple interactions
ISO
EXP
Glycochenodeoxycholic Acid results in increased activity of CASP9 protein
Sulfasalazine inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP9 protein]
CTD PMID:15767249 PMID:16322111 NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CFLAR CASP8 and FADD like apoptosis regulator multiple interactions
increases expression
EXP
ISO
Glycochenodeoxycholic Acid results in decreased expression of and results in increased phosphorylation of CFLAR protein
Glycochenodeoxycholic Acid results in increased expression of CFLAR protein
Glycochenodeoxycholic Acid promotes the reaction [lysophosphatidylethanolamine analog results in increased expression of CFLAR protein]; lysophosphatidylethanolamine analog promotes the reaction [Glycochenodeoxycholic Acid results in increased expression of CFLAR protein]
CTD PMID:25125499 NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYCS cytochrome c, somatic affects localization ISO Glycochenodeoxycholic Acid affects the localization of CYCS protein CTD PMID:15767249 NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions
increases expression
ISO
EXP
AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased expression of DDIT3 mRNA]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:23300732 PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions ISO
EXP
Glycochenodeoxycholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Glycochenodeoxycholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
CTD PMID:3783048 PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] CTD PMID:15802798 NCBI chr 7:81,699,006...81,770,438
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of Glycochenodeoxycholic Acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G HUWE1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1 multiple interactions EXP Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein] CTD PMID:21507240 NCBI chr  X:53,532,096...53,686,723
Ensembl chr  X:53,532,096...53,686,728
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32152650 PMID:32439580 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK1 protein]
CTD PMID:21507240 PMID:23300732 NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,754,500...21,867,680
Ensembl chr22:21,754,500...21,867,680
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases activity
multiple interactions
EXP
ISO
Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein
[AGT protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of MAPK3 protein]
CTD PMID:21507240 PMID:23300732 NCBI chr16:30,114,105...30,123,309
Ensembl chr16:30,114,105...30,123,506
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MCL1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases phosphorylation
EXP
ISO
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein]; [Glycochenodeoxycholic Acid results in increased phosphorylation of MCL1 protein] which results in decreased degradation of MCL1 protein; Glycochenodeoxycholic Acid inhibits the reaction [HUWE1 protein binds to MCL1 protein]
Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein; lysophosphatidylethanolamine analog inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of and results in increased degradation of MCL1 protein]
CTD PMID:21507240 PMID:25125499 NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,574,551...150,579,738
Ensembl chr 1:150,574,551...150,579,738
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G NOS2 nitric oxide synthase 2 increases expression ISO Glycochenodeoxycholic Acid results in increased expression of NOS2 mRNA CTD PMID:15767249 NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
JBrowse link
G NOS3 nitric oxide synthase 3 decreases expression
multiple interactions
EXP Glycochenodeoxycholic Acid results in decreased expression of NOS3; Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA; Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein
[Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Calcimycin inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 mRNA]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein]; Ubiquinone inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of NOS3]
CTD PMID:19837105 PMID:20020783 NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA CTD PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 increases cleavage ISO Glycochenodeoxycholic Acid results in increased cleavage of PARP1 protein CTD PMID:25125499 NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,691...226,408,093
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 increases uptake
multiple interactions
EXP SLC10A1 protein results in increased uptake of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
CTD PMID:29024779 PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; troglitazone sulfate inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases transport
multiple interactions
EXP SLCO1B1 protein results in increased transport of Glycochenodeoxycholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
CTD PMID:29933103 PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TFE3 transcription factor binding to IGHM enhancer 3 multiple interactions
decreases expression
EXP Acetylcysteine inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of TFE3 mRNA]; Glycochenodeoxycholic Acid results in decreased expression of and results in decreased activity of TFE3 protein; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of ATG5 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of BECN1 mRNA]; TFE3 protein inhibits the reaction [Glycochenodeoxycholic Acid results in decreased expression of MAP1LC3B mRNA] CTD PMID:32439580 NCBI chr  X:49,028,726...49,043,357
Ensembl chr  X:49,028,726...49,043,410
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 affects transport
multiple interactions
EXP ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA
CTD PMID:15791618 PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G IL10 interleukin 10 decreases abundance ISO IL10 gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:27580383 NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity
multiple interactions
EXP Glycocholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710 PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G POR cytochrome p450 oxidoreductase decreases abundance ISO POR gene mutant form results in decreased abundance of Glycocholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid] CTD PMID:32152650 PMID:32294204 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 increases abundance
multiple interactions
EXP SLCO1B1 SNP results in increased abundance of Glycocholic Acid
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA
CTD PMID:22022402 PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein; [Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Curcumin analog inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein]; Curcumin analog promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin promotes the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in decreased expression of and results in decreased activity of SOD2 protein]; Plant Extracts inhibits the reaction [[Sodium Cholate co-treated with Deoxycholic Acid co-treated with Glycocholic Acid co-treated with Taurocholic Acid] results in increased expression of and results in decreased activity of SOD2 protein] CTD PMID:22316666 PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB11 ATP binding cassette subfamily B member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA CTD PMID:32152650 NCBI chr 2:168,915,468...169,031,396
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC1 ATP binding cassette subfamily C member 1 multiple interactions EXP Glycodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] CTD PMID:16101123 NCBI chr16:15,949,616...16,143,062
Ensembl chr16:15,949,577...16,143,074
Ensembl chr16:15,949,577...16,143,074
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCC4 ATP binding cassette subfamily C member 4 multiple interactions EXP [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA CTD PMID:32152650 NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
JBrowse link
G AKR1A1 aldo-keto reductase family 1 member A1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA CTD PMID:32152650 NCBI chr 1:45,550,779...45,570,051
Ensembl chr 1:45,550,543...45,570,049
JBrowse link
G AKR7A2 aldo-keto reductase family 7 member A2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA CTD PMID:32152650 NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,146
Ensembl chr 1:19,303,965...19,312,146
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 NCBI chr 1:19,274,229...19,289,362
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G AOX1 aldehyde oxidase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA CTD PMID:32152650 NCBI chr 2:200,585,952...200,677,064
Ensembl chr 2:200,586,014...200,677,064
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA CTD PMID:32152650 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,320...161,964,070
JBrowse link
G ATG7 autophagy related 7 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA CTD PMID:32152650 NCBI chr 3:11,272,348...11,564,652
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G CASP3 caspase 3 multiple interactions ISO [Glycodeoxycholic Acid co-treated with Ceruletide] results in decreased activity of CASP3 protein CTD PMID:18832452 NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
JBrowse link
G CAT catalase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CBR1 carbonyl reductase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA CTD PMID:32152650 NCBI chr21:36,070,024...36,073,164
Ensembl chr21:36,069,941...36,073,166
JBrowse link
G CCR2 C-C motif chemokine receptor 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA CTD PMID:32152650 NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,744...46,360,940
Ensembl chr 3:46,353,744...46,360,940
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB1 DnaJ heat shock protein family (Hsp40) member B1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA CTD PMID:32152650 NCBI chr19:14,514,769...14,530,597
Ensembl chr19:14,514,769...14,529,770
Ensembl chr19:14,514,769...14,529,770
JBrowse link
G DNAJB11 DnaJ heat shock protein family (Hsp40) member B11 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA CTD PMID:32152650 NCBI chr 3:186,570,720...186,585,793
Ensembl chr 3:186,567,403...186,585,800
JBrowse link
G DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA CTD PMID:32152650 NCBI chr 7:157,337,004...157,417,439
Ensembl chr 7:157,335,381...157,417,439
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA CTD PMID:32152650 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC1 DnaJ heat shock protein family (Hsp40) member C1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA CTD PMID:32152650 NCBI chr10:21,756,548...22,003,763
Ensembl chr10:21,756,548...22,003,769
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,041...182,794,464
Ensembl chr 2:182,716,041...182,794,464
JBrowse link
G DNAJC16 DnaJ heat shock protein family (Hsp40) member C16 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA CTD PMID:32152650 NCBI chr 1:15,526,694...15,571,987
Ensembl chr 1:15,526,813...15,592,379
JBrowse link
G DNAJC18 DnaJ heat shock protein family (Hsp40) member C18 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA CTD PMID:32152650 NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
JBrowse link
G DNAJC19 DnaJ heat shock protein family (Hsp40) member C19 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA CTD PMID:32152650 NCBI chr 3:180,983,709...180,989,838
Ensembl chr 3:180,983,709...180,989,774
JBrowse link
G DNAJC21 DnaJ heat shock protein family (Hsp40) member C21 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA CTD PMID:32152650 NCBI chr 5:34,929,540...34,958,964
Ensembl chr 5:34,929,559...34,958,964
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA CTD PMID:32152650 NCBI chr13:95,677,139...95,794,988
Ensembl chr13:95,677,139...95,794,988
JBrowse link
G DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA CTD PMID:32152650 NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,241,954...73,247,255
Ensembl chr10:73,183,362...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G ENC1 ectodermal-neural cortex 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA CTD PMID:32152650 NCBI chr 5:74,627,409...74,640,728
Ensembl chr 5:74,627,406...74,641,424
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,092...225,845,563
Ensembl chr 1:225,810,092...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,473...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GPX2 glutathione peroxidase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA CTD PMID:32152650 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,905
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,827
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,799
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTK1 glutathione S-transferase kappa 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA CTD PMID:32152650 NCBI chr 7:143,263,441...143,269,115
Ensembl chr 7:143,244,093...143,270,854
JBrowse link
G GSTM1 glutathione S-transferase mu 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA CTD PMID:32152650 NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
JBrowse link
G GSTM2 glutathione S-transferase mu 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA CTD PMID:32152650 NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,076...109,665,497
Ensembl chr 1:109,656,099...109,674,836
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA CTD PMID:32152650 NCBI chr16:56,932,142...56,944,864
Ensembl chr16:56,932,142...56,944,864
JBrowse link
G HMOX1 heme oxygenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA CTD PMID:32152650 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,207
Ensembl chr22:35,380,361...35,394,207
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,343
JBrowse link
G HSPB8 heat shock protein family B (small) member 8 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA CTD PMID:32152650 NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
Ensembl chr12:119,171,555...119,224,855
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
Ensembl chr 1:58,780,791...58,784,047
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G MAF MAF bZIP transcription factor multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA CTD PMID:32152650 NCBI chr16:79,202,624...79,601,952
Ensembl chr16:79,585,843...79,600,737
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAFG MAF bZIP transcription factor G multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA CTD PMID:32152650 NCBI chr17:81,918,270...81,927,735
Ensembl chr17:81,918,270...81,927,735
JBrowse link
G MAFK MAF bZIP transcription factor K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA CTD PMID:32152650 NCBI chr 7:1,530,702...1,543,043
Ensembl chr 7:1,530,702...1,543,043
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA CTD PMID:32152650 NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,817...66,492,312
Ensembl chr15:66,386,817...66,492,312
JBrowse link
G MAP2K2 mitogen-activated protein kinase kinase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA CTD PMID:32152650 NCBI chr19:4,090,321...4,124,184
Ensembl chr19:4,090,321...4,124,129
Ensembl chr19:4,090,321...4,124,129
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPK9 mitogen-activated protein kinase 9 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA CTD PMID:32152650 NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA CTD PMID:32152650 NCBI chr 3:50,611,877...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MGST2 microsomal glutathione S-transferase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA CTD PMID:32152650 NCBI chr 4:139,665,725...139,754,608
Ensembl chr 4:139,665,768...139,740,745
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA CTD PMID:32152650 NCBI chr16:74,671,855...74,700,889
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MYL9 myosin light chain 9 multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] CTD PMID:29660437 NCBI chr20:36,541,519...36,551,447
Ensembl chr20:36,541,497...36,551,447
JBrowse link
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA CTD PMID:32152650 NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668
JBrowse link
G NQO2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA CTD PMID:32152650 NCBI chr 6:2,999,894...3,019,755
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
Ensembl chr 6:2,987,987...3,021,850
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 increases activity
multiple interactions
EXP Glycodeoxycholic Acid results in increased activity of NR1H4 protein
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
CTD PMID:17567710 PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,485
Ensembl chr 3:119,780,484...119,818,485
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA CTD PMID:32152650 NCBI chr 1:161,229,666...161,238,623
Ensembl chr 1:161,229,666...161,238,302
Ensembl chr 1:161,229,666...161,238,302
JBrowse link
G PIK3C2B phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA CTD PMID:32152650 NCBI chr 1:204,422,633...204,494,815
Ensembl chr 1:204,422,628...204,494,724
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA CTD PMID:32152650 NCBI chr12:18,242,946...18,716,861
Ensembl chr12:18,242,961...18,648,416
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA CTD PMID:32152650 NCBI chr18:41,955,226...42,087,830
Ensembl chr18:41,955,234...42,087,830
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA CTD PMID:32152650 NCBI chr 5:68,215,737...68,301,821
Ensembl chr 5:68,215,756...68,301,821
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of Glycodeoxycholic Acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G PPP1R12A protein phosphatase 1 regulatory subunit 12A multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] CTD PMID:29660437 NCBI chr12:79,773,563...79,935,460
Ensembl chr12:79,773,563...79,935,460
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,622,955...39,708,124
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G RAP1A RAP1A, member of RAS oncogene family multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA CTD PMID:32152650 NCBI chr 1:111,542,009...111,716,695
Ensembl chr 1:111,542,218...111,716,691
JBrowse link
G RHOA ras homolog family member A multiple interactions ISO Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] CTD PMID:29660437 NCBI chr 3:49,359,145...49,411,976
Ensembl chr 3:49,359,145...49,412,998
Ensembl chr 3:49,359,145...49,412,998
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,991...3,115,187
Ensembl chr 6:3,063,991...3,115,187
JBrowse link
G RRAS2 RAS related 2 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA CTD PMID:32152650 NCBI chr11:14,277,920...14,364,506
Ensembl chr11:14,277,922...14,364,506
JBrowse link
G SCARB1 scavenger receptor class B member 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA CTD PMID:32152650 NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
JBrowse link
G SERPINE1 serpin family E member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA CTD PMID:32152650 NCBI chr 1:86,704,570...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA CTD PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC51A solute carrier family 51 subunit alpha multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA CTD PMID:32152650 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B solute carrier family 51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA CTD PMID:32152650 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA CTD PMID:32152650 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G STIP1 stress induced phosphoprotein 1 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA CTD PMID:32152650 NCBI chr11:64,185,272...64,204,543
Ensembl chr11:64,185,272...64,204,543
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G UBE2K ubiquitin conjugating enzyme E2 K multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA CTD PMID:32152650 NCBI chr 4:39,698,136...39,782,792
Ensembl chr 4:39,698,109...39,782,792
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
G USP14 ubiquitin specific peptidase 14 multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA CTD PMID:32152650 NCBI chr18:158,557...214,629
Ensembl chr18:158,383...214,629
JBrowse link
G VCP valosin containing protein multiple interactions EXP [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA CTD PMID:32152650 NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
Ensembl chr 9:35,056,064...35,072,627
JBrowse link
glycolithocholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSD11B1 hydroxysteroid 11-beta dehydrogenase 1 decreases abundance ISO HSD11B1 gene mutant form results in decreased abundance of glycolithocholic acid CTD PMID:25061560 NCBI chr 1:209,686,179...209,734,929
Ensembl chr 1:209,686,178...209,734,949
JBrowse link
G POR cytochrome p450 oxidoreductase increases abundance ISO POR gene mutant form results in increased abundance of glycolithocholic acid CTD PMID:25034404 NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 multiple interactions EXP SLCO1B1 protein binds to and results in increased transport of glycolithocholic acid analog CTD PMID:29933103 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
glycoursodeoxycholic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions ISO glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G EDN1 endothelin 1 decreases expression EXP glycoursodeoxycholic acid results in decreased expression of EDN1 protein CTD PMID:15556138 NCBI chr 6:12,256,463...12,297,194
Ensembl chr 6:12,290,361...12,297,194
JBrowse link
G SLC4A2 solute carrier family 4 member 2 multiple interactions EXP [glycoursodeoxycholic acid co-treated with Dexamethasone] results in increased expression of SLC4A2 mRNA alternative form CTD PMID:18188457 NCBI chr 7:151,058,200...151,076,527
Ensembl chr 7:151,057,210...151,076,526
JBrowse link
G TP53 tumor protein p53 multiple interactions ISO glycoursodeoxycholic acid inhibits the reaction [TP53 protein results in increased expression of BAX mRNA] CTD PMID:17881359 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538
Ensembl chr17:7,661,779...7,687,538
JBrowse link
glyphosate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AAK1 AP2 associated kinase 1 decreases expression EXP glyphosate results in decreased expression of AAK1 mRNA CTD PMID:28711546 NCBI chr 2:69,457,997...69,643,739
Ensembl chr 2:69,457,997...69,674,349
JBrowse link
G ABHD16A abhydrolase domain containing 16A, phospholipase increases methylation ISO glyphosate results in increased methylation of ABHD16A gene CTD PMID:31011160 NCBI chr 6:31,686,955...31,703,324
Ensembl chr 6:31,686,955...31,703,356
JBrowse link
G ABHD2 abhydrolase domain containing 2, acylglycerol lipase increases expression EXP glyphosate results in increased expression of ABHD2 mRNA CTD PMID:28711546 NCBI chr15:89,088,422...89,202,355
Ensembl chr15:89,087,459...89,202,355
JBrowse link
G ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase increases expression EXP glyphosate results in increased expression of ABL1 mRNA CTD PMID:31874349 NCBI chr 9:130,713,043...130,887,675
Ensembl chr 9:130,713,016...130,887,675
JBrowse link
G ACACA acetyl-CoA carboxylase alpha increases expression ISO glyphosate results in increased expression of ACACA mRNA CTD PMID:31374489 NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
JBrowse link
G ACHE acetylcholinesterase (Cartwright blood group) decreases activity ISO glyphosate results in decreased activity of ACHE protein CTD PMID:28627408 PMID:30682438 PMID:32067069 NCBI chr 7:100,889,994...100,896,994
Ensembl chr 7:100,889,994...100,896,974
JBrowse link
G ACR acrosin increases methylation ISO glyphosate results in increased methylation of ACR gene CTD PMID:31011160 NCBI chr22:50,738,204...50,745,339
Ensembl chr22:50,738,196...50,745,339
JBrowse link
G ACTB actin beta decreases expression EXP glyphosate results in decreased expression of ACTB mRNA CTD PMID:31295307 NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
Ensembl chr 7:5,526,409...5,563,902
JBrowse link
G ACTG2 actin gamma 2, smooth muscle affects expression ISO glyphosate affects the expression of ACTG2 protein CTD PMID:20045496 NCBI chr 2:73,893,008...73,919,865
Ensembl chr 2:73,892,314...73,919,865
JBrowse link
G ACTR3B actin related protein 3B increases methylation ISO glyphosate results in increased methylation of ACTR3B gene CTD PMID:31011160 NCBI chr 7:152,759,752...153,070,979
Ensembl chr 7:152,759,749...152,855,378
JBrowse link
G ACVR1 activin A receptor type 1 increases expression EXP glyphosate results in increased expression of ACVR1 mRNA CTD PMID:31295307 NCBI chr 2:157,736,446...157,876,330
Ensembl chr 2:157,736,444...157,876,330
Ensembl chr 2:157,736,444...157,876,330
JBrowse link
G ACVR2B activin A receptor type 2B decreases expression
increases expression
EXP glyphosate results in decreased expression of ACVR2B mRNA
glyphosate results in increased expression of ACVR2B mRNA
CTD PMID:31295307 NCBI chr 3:38,453,890...38,493,142
Ensembl chr 3:38,453,890...38,493,142
JBrowse link
G ADAM17 ADAM metallopeptidase domain 17 decreases expression EXP glyphosate results in decreased expression of ADAM17 mRNA CTD PMID:31295307 NCBI chr 2:9,488,486...9,555,830
Ensembl chr 2:9,488,486...9,556,732
JBrowse link
G ADAMTS19 ADAM metallopeptidase with thrombospondin type 1 motif 19 increases methylation ISO glyphosate results in increased methylation of ADAMTS19 gene CTD PMID:31011160 NCBI chr 5:129,460,281...129,738,683
Ensembl chr 5:129,460,281...129,738,683
JBrowse link
G ADARB1 adenosine deaminase RNA specific B1 increases methylation ISO glyphosate results in increased methylation of ADARB1 gene CTD PMID:31011160 NCBI chr21:45,074,578...45,226,563
Ensembl chr21:45,073,853...45,226,560
JBrowse link
G ADD1 adducin 1 increases methylation ISO glyphosate results in increased methylation of ADD1 gene CTD PMID:31011160 NCBI chr 4:2,843,844...2,930,065
Ensembl chr 4:2,843,857...2,930,076
JBrowse link
G ADD3 adducin 3 increases methylation ISO glyphosate results in increased methylation of ADD3 gene CTD PMID:31011160 NCBI chr10:109,996,365...110,135,565
Ensembl chr10:109,996,368...110,135,565
JBrowse link
G ADGRV1 adhesion G protein-coupled receptor V1 decreases methylation ISO glyphosate results in decreased methylation of ADGRV1 gene CTD PMID:31011160 NCBI chr 5:90,558,796...91,164,437
Ensembl chr 5:90,529,344...91,164,437
JBrowse link
G AIFM1 apoptosis inducing factor mitochondria associated 1 decreases expression EXP glyphosate results in decreased expression of AIFM1 mRNA CTD PMID:31295307 NCBI chr  X:130,129,362...130,165,841
Ensembl chr  X:130,124,666...130,165,879
Ensembl chr  X:130,124,666...130,165,879
JBrowse link
G AKR1B1 aldo-keto reductase family 1 member B decreases expression ISO glyphosate results in decreased expression of AKR1B1 mRNA CTD PMID:26302742 NCBI chr 7:134,442,350...134,459,239
Ensembl chr 7:134,442,356...134,459,284
JBrowse link
G AKT1 AKT serine/threonine kinase 1 decreases expression EXP glyphosate results in decreased expression of AKT1 mRNA CTD PMID:31295307 PMID:31874349 NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751
JBrowse link
G ALB albumin affects binding
increases expression
affects expression
multiple interactions
EXP
ISO
glyphosate binds to ALB protein
glyphosate results in increased expression of ALB mRNA; glyphosate results in increased expression of ALB protein
glyphosate affects the expression of ALB protein
Zinc inhibits the reaction [glyphosate results in increased expression of ALB protein]
CTD PMID:18035550 PMID:20045496 PMID:25067936 PMID:26302742 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
JBrowse link
G ALDH1A3 aldehyde dehydrogenase 1 family member A3 decreases expression EXP glyphosate results in decreased expression of ALDH1A3 mRNA CTD PMID:28711546 NCBI chr15:100,879,831...100,916,626
Ensembl chr15:100,877,714...100,916,626
JBrowse link
G ALDOA aldolase, fructose-bisphosphate A increases methylation ISO glyphosate results in increased methylation of ALDOART2 gene CTD PMID:31011160 NCBI chr16:30,053,151...30,070,414
Ensembl chr16:30,053,090...30,070,420
Ensembl chr16:30,053,090...30,070,420
Ensembl chr16:30,053,090...30,070,420
JBrowse link
G ALG5 ALG5 dolichyl-phosphate beta-glucosyltransferase decreases expression ISO glyphosate results in decreased expression of ALG5 mRNA CTD PMID:26302742 NCBI chr13:36,949,738...36,999,367
Ensembl chr13:36,949,738...37,000,261
Ensembl chr13:36,949,738...37,000,261
JBrowse link
G ALG9 ALG9 alpha-1,2-mannosyltransferase increases expression EXP glyphosate results in increased expression of ALG9 mRNA CTD PMID:28711546 NCBI chr11:111,776,096...111,871,581
Ensembl chr11:111,782,195...111,871,581
JBrowse link
G AMOTL1 angiomotin like 1 increases methylation ISO glyphosate results in increased methylation of AMOTL1 gene CTD PMID:31011160 NCBI chr11:94,706,418...94,876,748
Ensembl chr11:94,706,431...94,876,748
JBrowse link
G ANAPC1 anaphase promoting complex subunit 1 decreases expression EXP glyphosate results in decreased expression of ANAPC1 mRNA CTD PMID:31295307 NCBI chr 2:111,766,150...111,884,196
Ensembl chr 2:111,611,639...111,884,690
JBrowse link
G ANAPC13 anaphase promoting complex subunit 13 decreases expression EXP glyphosate results in decreased expression of ANAPC13 mRNA CTD PMID:31295307 NCBI chr 3:134,477,704...134,486,023
Ensembl chr 3:134,477,706...134,486,716
JBrowse link
G ANAPC4 anaphase promoting complex subunit 4 decreases methylation ISO glyphosate results in decreased methylation of ANAPC4 gene CTD PMID:31011160 NCBI chr 4:25,377,263...25,418,498
Ensembl chr 4:25,377,263...25,418,498
Ensembl chr 4:25,377,263...25,418,498
JBrowse link
G ANAPC5 anaphase promoting complex subunit 5 decreases methylation
decreases expression
ISO
EXP
glyphosate results in decreased methylation of ANAPC5 gene
glyphosate results in decreased expression of ANAPC5 mRNA
CTD PMID:31011160 PMID:31295307 NCBI chr12:121,308,245...121,354,209
Ensembl chr12:121,308,245...121,399,896
JBrowse link
G ANGPT1 angiopoietin 1 decreases methylation
increases expression
decreases expression
ISO
EXP
glyphosate results in decreased methylation of ANGPT1 gene
glyphosate results in increased expression of ANGPT1 mRNA
glyphosate results in decreased expression of ANGPT1 mRNA
CTD PMID:31011160 PMID:31295307 NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055
JBrowse link
G ANKRD13A ankyrin repeat domain 13A increases methylation ISO glyphosate results in increased methylation of ANKRD13A gene CTD PMID:31011160 NCBI chr12:109,999,169...110,039,763
Ensembl chr12:109,999,186...110,039,763
JBrowse link
G ANKRD17 ankyrin repeat domain 17 increases expression ISO glyphosate results in increased expression of ANKRD17 mRNA CTD PMID:26302742 NCBI chr 4:73,073,376...73,259,766
Ensembl chr 4:73,073,376...73,258,798
JBrowse link
G ANXA2 annexin A2 increases expression ISO glyphosate results in increased expression of ANXA2 protein CTD PMID:20045496 NCBI chr15:60,347,151...60,398,025
Ensembl chr15:60,347,134...60,402,883
JBrowse link
G ANXA4 annexin A4 increases methylation ISO glyphosate results in increased methylation of ANXA4 gene CTD PMID:31011160 NCBI chr 2:69,643,808...69,827,112
Ensembl chr 2:69,644,425...69,827,112
JBrowse link
G AOPEP aminopeptidase O (putative) decreases methylation ISO glyphosate results in decreased methylation of AOPEP gene CTD PMID:31011160 NCBI chr 9:94,726,669...95,148,264
Ensembl chr 9:94,726,701...95,087,218
Ensembl chr 9:94,726,701...95,087,218
JBrowse link
G AP4E1 adaptor related protein complex 4 subunit epsilon 1 increases methylation ISO glyphosate results in increased methylation of AP4E1 gene CTD PMID:31011160 NCBI chr15:50,908,569...51,005,900
Ensembl chr15:50,908,672...51,005,895
JBrowse link
G APAF1 apoptotic peptidase activating factor 1 decreases expression
increases expression
EXP glyphosate results in decreased expression of APAF1 mRNA; glyphosate results in decreased expression of APAF1 protein
glyphosate results in increased expression of APAF1 mRNA
CTD PMID:24073338 PMID:31295307 PMID:31874349 NCBI chr12:98,645,141...98,735,433
Ensembl chr12:98,645,141...98,735,433
Ensembl chr12:98,645,141...98,735,433
JBrowse link
G APEX2 apurinic/apyrimidinic endodeoxyribonuclease 2 decreases expression EXP glyphosate results in decreased expression of APEX2 mRNA CTD PMID:31295307 NCBI chr  X:55,000,363...55,009,057
Ensembl chr  X:55,000,363...55,009,057
JBrowse link
G APIP APAF1 interacting protein decreases expression ISO glyphosate results in decreased expression of APIP mRNA CTD PMID:26302742 NCBI chr11:34,882,295...34,916,411
Ensembl chr11:34,853,094...34,916,379
JBrowse link
G APOO apolipoprotein O increases methylation ISO glyphosate results in increased methylation of APOO gene CTD PMID:31011160 NCBI chr  X:23,833,348...23,907,938
Ensembl chr  X:23,833,353...23,907,938
JBrowse link
G APP amyloid beta precursor protein increases expression EXP glyphosate results in increased expression of APP mRNA CTD PMID:31874349 NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,550...26,171,128
JBrowse link
G AR androgen receptor multiple interactions
increases expression
decreases expression
decreases activity
EXP
ISO
[glyphosate co-treated with Herbicides] results in decreased activity of AR protein
glyphosate results in increased expression of AR protein
glyphosate results in decreased expression of AR mRNA
glyphosate results in decreased activity of AR protein
CTD PMID:19539684 PMID:30447247 NCBI chr  X:67,544,021...67,730,619
Ensembl chr  X:67,544,021...67,730,619
JBrowse link
G ARF4 ADP ribosylation factor 4 increases expression EXP glyphosate results in increased expression of ARF4 mRNA CTD PMID:17984146 NCBI chr 3:57,571,363...57,597,344
Ensembl chr 3:57,571,363...57,598,220
JBrowse link
G ARF6 ADP ribosylation factor 6 increases expression EXP glyphosate results in increased expression of ARF6 mRNA CTD PMID:31295307 NCBI chr14:49,893,082...49,897,054
Ensembl chr14:49,893,082...49,897,054
JBrowse link
G ARFGAP1 ADP ribosylation factor GTPase activating protein 1 increases expression ISO glyphosate results in increased expression of ARFGAP1 mRNA CTD PMID:26302742 NCBI chr20:63,272,813...63,289,790
Ensembl chr20:63,272,785...63,289,790
JBrowse link
G ARHGAP22 Rho GTPase activating protein 22 decreases methylation ISO glyphosate results in decreased methylation of ARHGAP22 gene CTD PMID:31011160 NCBI chr10:48,429,831...48,656,265
Ensembl chr10:48,446,036...48,656,265
Ensembl chr10:48,446,036...48,656,265
JBrowse link
G ARHGAP31 Rho GTPase activating protein 31 increases methylation ISO glyphosate results in increased methylation of ARHGAP31 gene CTD PMID:31011160 NCBI chr 3:119,294,289...119,420,714
Ensembl chr 3:119,294,383...119,420,714
JBrowse link
G ARHGEF12 Rho guanine nucleotide exchange factor 12 decreases methylation ISO glyphosate results in decreased methylation of ARHGEF12 gene CTD PMID:31011160 NCBI chr11:120,336,276...120,489,937
Ensembl chr11:120,336,413...120,489,937
JBrowse link
G ARHGEF18 Rho/Rac guanine nucleotide exchange factor 18 decreases methylation ISO glyphosate results in decreased methylation of ARHGEF18 gene CTD PMID:31011160 NCBI chr19:7,348,901...7,476,990
Ensembl chr19:7,382,834...7,470,241
Ensembl chr19:7,382,834...7,470,241
Ensembl chr19:7,382,834...7,470,241
JBrowse link
G ARID4B AT-rich interaction domain 4B increases expression ISO glyphosate results in increased expression of ARID4B mRNA CTD PMID:26302742 NCBI chr 1:235,166,895...235,328,224
Ensembl chr 1:235,131,634...235,328,219
JBrowse link
G ARL6IP1 ADP ribosylation factor like GTPase 6 interacting protein 1 decreases expression ISO glyphosate results in decreased expression of ARL6IP1 mRNA CTD PMID:26302742 NCBI chr16:18,791,667...18,801,549
Ensembl chr16:18,791,669...18,801,572
JBrowse link
G ARMC9 armadillo repeat containing 9 increases methylation ISO glyphosate results in increased methylation of ARMC9 gene CTD PMID:31011160 NCBI chr 2:231,198,628...231,394,991
Ensembl chr 2:231,198,546...231,376,848
Ensembl chr 2:231,198,546...231,376,848
JBrowse link
G ARPC1A actin related protein 2/3 complex subunit 1A increases methylation ISO glyphosate results in increased methylation of ARPC1A gene CTD PMID:31011160 NCBI chr 7:99,325,898...99,366,262
Ensembl chr 7:99,325,898...99,366,262
JBrowse link
G ARRB1 arrestin beta 1 decreases expression EXP glyphosate results in decreased expression of ARRB1 mRNA CTD PMID:31295307 NCBI chr11:75,260,122...75,351,662
Ensembl chr11:75,260,122...75,351,705
JBrowse link
G ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 increases methylation ISO glyphosate results in increased methylation of ASAP2 gene CTD PMID:31011160 NCBI chr 2:9,206,812...9,405,678
Ensembl chr 2:9,206,765...9,405,683
JBrowse link
G ASB10 ankyrin repeat and SOCS box containing 10 increases methylation ISO glyphosate results in increased methylation of ASB10 gene CTD PMID:31011160 NCBI chr 7:151,175,698...151,187,792
Ensembl chr 7:151,175,698...151,187,832
JBrowse link
G ASIC2 acid sensing ion channel subunit 2 increases methylation ISO glyphosate results in increased methylation of ASIC2 gene CTD PMID:31011160 NCBI chr17:33,013,087...34,156,768
Ensembl chr17:33,013,087...34,174,964
JBrowse link
G ATF4 activating transcription factor 4 increases expression EXP glyphosate results in increased expression of ATF4 mRNA CTD PMID:31295307 NCBI chr22:39,514,494...39,522,686
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
Ensembl chr22:39,519,672...39,522,683
JBrowse link
G ATG12 autophagy related 12 increases expression EXP
ISO
glyphosate results in increased expression of ATG12 mRNA
glyphosate results in increased expression of ATG12 protein
CTD PMID:31352102 PMID:31874349 NCBI chr 5:115,828,200...115,841,565
Ensembl chr 5:115,828,200...115,841,837
JBrowse link
G ATG14 autophagy related 14 increases expression ISO glyphosate results in increased expression of ATG14 mRNA CTD PMID:31352102 NCBI chr14:55,366,391...55,411,830
Ensembl chr14:55,366,391...55,411,830
Ensembl chr14:55,366,391...55,411,830
JBrowse link
G ATG3 autophagy related 3 increases expression EXP glyphosate results in increased expression of ATG3 mRNA CTD PMID:31874349 NCBI chr 3:112,532,510...112,561,962
Ensembl chr 3:112,532,510...112,562,046
JBrowse link
G ATG5 autophagy related 5 increases expression EXP glyphosate results in increased expression of ATG5 mRNA CTD PMID:31874349 NCBI chr 6:106,184,476...106,325,789
Ensembl chr 6:106,045,423...106,325,791
JBrowse link
G ATP13A1 ATPase 13A1 increases expression ISO glyphosate results in increased expression of ATP13A1 mRNA CTD PMID:26302742 NCBI chr19:19,645,198...19,663,676
Ensembl chr19:19,645,198...19,663,676
JBrowse link
G ATP5F1B ATP synthase F1 subunit beta decreases expression ISO glyphosate results in decreased expression of ATP5F1B mRNA CTD PMID:26302742 NCBI chr12:56,638,175...56,645,984
Ensembl chr12:56,638,175...56,645,984
JBrowse link
G ATP5F1D ATP synthase F1 subunit delta decreases expression ISO glyphosate results in decreased expression of ATP5F1D mRNA CTD PMID:26302742 NCBI chr19:1,241,751...1,244,825
Ensembl chr19:1,241,746...1,244,825
JBrowse link
G ATP8B4 ATPase phospholipid transporting 8B4 (putative) decreases methylation ISO glyphosate results in decreased methylation of ATP8B4 gene CTD PMID:31011160 NCBI chr15:49,858,238...50,181,851
Ensembl chr15:49,858,238...50,182,817
JBrowse link
G ATP9A ATPase phospholipid transporting 9A (putative) increases expression EXP glyphosate results in increased expression of ATP9A mRNA CTD PMID:17984146 NCBI chr20:51,596,514...51,768,390
Ensembl chr20:51,596,514...51,768,390
JBrowse link
G ATXN1 ataxin 1 increases expression ISO glyphosate results in increased expression of ATXN1 mRNA CTD PMID:26302742 NCBI chr 6:16,299,112...16,761,490
Ensembl chr 6:16,299,112...16,761,491
JBrowse link
G AXIN2 axin 2 increases methylation ISO glyphosate results in increased methylation of AXIN2 gene CTD PMID:31011160 NCBI chr17:65,528,563...65,561,648
Ensembl chr17:65,528,563...65,561,648
JBrowse link
G B3GAT2 beta-1,3-glucuronyltransferase 2 decreases methylation ISO glyphosate results in decreased methylation of B3GAT2 gene CTD PMID:31011160 NCBI chr 6:70,856,679...70,957,060
Ensembl chr 6:70,856,679...70,957,060
JBrowse link
G B3GLCT beta 3-glucosyltransferase increases methylation ISO glyphosate results in increased methylation of B3GLCT gene CTD PMID:31011160 NCBI chr13:31,199,975...31,332,276
Ensembl chr13:31,199,975...31,332,276
JBrowse link
G B4GALT2 beta-1,4-galactosyltransferase 2 increases methylation ISO glyphosate results in increased methylation of B4GALT2 gene CTD PMID:31011160 NCBI chr 1:43,979,210...43,991,171
Ensembl chr 1:43,978,943...43,991,170
JBrowse link
G B4GALT6 beta-1,4-galactosyltransferase 6 decreases methylation ISO glyphosate results in decreased methylation of B4GALT6 gene CTD PMID:31011160 NCBI chr18:31,622,246...31,724,670
Ensembl chr18:31,622,247...31,685,836
JBrowse link
G BAMBI BMP and activin membrane bound inhibitor decreases expression EXP glyphosate results in decreased expression of BAMBI mRNA CTD PMID:31295307 NCBI chr10:28,677,521...28,682,932
Ensembl chr10:28,677,510...28,682,932
JBrowse link
G BASP1 brain abundant membrane attached signal protein 1 decreases methylation ISO glyphosate results in decreased methylation of BASP1 gene CTD PMID:31011160 NCBI chr 5:17,216,823...17,276,834
Ensembl chr 5:17,065,598...17,276,843
JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression
increases expression
multiple interactions
EXP
ISO
glyphosate results in decreased expression of BAX protein
glyphosate results in increased expression of BAX mRNA
XAF1 protein affects the reaction [glyphosate results in increased expression of BAX protein]
glyphosate results in increased expression of BAX mRNA; glyphosate results in increased expression of BAX protein
[Surface-Active Agents co-treated with glyphosate] results in increased expression of BAX protein
CTD PMID:23099315 PMID:24073338 PMID:29908847 PMID:30785197 PMID:31295307 PMID:31352102 PMID:31874349 NCBI chr19:48,954,825...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BAZ2A bromodomain adjacent to zinc finger domain 2A increases expression ISO glyphosate results in increased expression of BAZ2A mRNA CTD PMID:26302742 NCBI chr12:56,595,596...56,636,816
Ensembl chr12:56,595,596...56,636,816
JBrowse link
G BCHE butyrylcholinesterase decreases activity
multiple interactions
EXP glyphosate results in decreased activity of BCHE protein
CYP1A1 gene SNP promotes the reaction [glyphosate results in decreased activity of BCHE protein]
CTD PMID:31836050 NCBI chr 3:165,772,904...165,837,423
Ensembl chr 3:165,772,904...165,837,462
JBrowse link
G BCL10 BCL10 immune signaling adaptor decreases expression ISO glyphosate results in decreased expression of BCL10 mRNA CTD PMID:26302742 NCBI chr 1:85,265,776...85,276,632
Ensembl chr 1:85,265,776...85,276,632
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
decreases expression
increases expression
ISO
EXP
[Surface-Active Agents co-treated with glyphosate] results in decreased expression of BCL2 protein
glyphosate results in decreased expression of BCL2 mRNA
glyphosate results in increased expression of BCL2 mRNA
glyphosate results in decreased expression of BCL2 mRNA; glyphosate results in decreased expression of BCL2 protein
glyphosate results in increased expression of BCL2 mRNA; glyphosate results in increased expression of BCL2 protein
CTD PMID:23099315 PMID:24073338 PMID:29908847 PMID:30785197 PMID:31352102 PMID:31751608 PMID:31874349 NCBI chr18:63,123,346...63,320,280
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BCL2A1 BCL2 related protein A1 increases expression EXP glyphosate results in increased expression of BCL2A1 mRNA CTD PMID:31874349 NCBI chr15:79,960,892...79,971,196
Ensembl chr15:79,960,892...79,971,196
JBrowse link
G BCL2L1 BCL2 like 1 increases expression EXP glyphosate results in increased expression of BCL2L1 mRNA CTD PMID:17984146 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G BDNF brain derived neurotrophic factor decreases expression ISO glyphosate results in decreased expression of BDNF mRNA CTD PMID:32067069 NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
JBrowse link
G BECN1 beclin 1 increases response to substance
increases expression
ISO BECN1 results in increased susceptibility to glyphosate
glyphosate results in increased expression of BECN1 mRNA
CTD PMID:22504123 PMID:26302742 NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
JBrowse link
G BID BH3 interacting domain death agonist decreases expression EXP glyphosate results in decreased expression of BID mRNA CTD PMID:31295307 NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
JBrowse link
G BIRC2 baculoviral IAP repeat containing 2 increases expression
decreases expression
EXP glyphosate results in increased expression of BIRC2 mRNA
glyphosate results in decreased expression of BIRC2 mRNA
CTD PMID:31295307 PMID:31874349 NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
JBrowse link
G BLZF1 basic leucine zipper nuclear factor 1 increases methylation ISO glyphosate results in increased methylation of BLZF1 gene CTD PMID:31011160 NCBI chr 1:169,368,195...169,396,575
Ensembl chr 1:169,367,970...169,396,540
JBrowse link
G BMP2 bone morphogenetic protein 2 decreases expression ISO glyphosate results in decreased expression of BMP2 mRNA CTD PMID:27486271 NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
JBrowse link
G BMP5 bone morphogenetic protein 5 decreases expression EXP glyphosate results in decreased expression of BMP5 mRNA CTD PMID:31295307 NCBI chr 6:55,753,653...55,875,590
Ensembl chr 6:55,753,653...55,875,590
JBrowse link
G BMPR1A bone morphogenetic protein receptor type 1A decreases expression EXP glyphosate results in decreased expression of BMPR1A mRNA CTD PMID:31295307 NCBI chr10:86,755,786...86,927,969
Ensembl chr10:86,756,601...86,932,838
Ensembl chr10:86,756,601...86,932,838
JBrowse link
G BMPR1B bone morphogenetic protein receptor type 1B decreases expression EXP glyphosate results in decreased expression of BMPR1B mRNA CTD PMID:31295307 NCBI chr 4:94,757,955...95,158,453
Ensembl chr 4:94,757,955...95,158,448
JBrowse link
G BNIP3 BCL2 interacting protein 3 decreases expression EXP glyphosate results in decreased expression of BNIP3 mRNA CTD PMID:31295307 NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,966,455...131,982,013
JBrowse link
G BOLA1 bolA family member 1 decreases methylation ISO glyphosate results in decreased methylation of BOLA1 gene CTD PMID:31011160 NCBI chr 1:149,899,568...149,900,795
Ensembl chr 1:149,887,890...149,900,798
JBrowse link
G BRAP BRCA1 associated protein increases expression
decreases expression
EXP glyphosate results in increased expression of BRAP mRNA
glyphosate results in decreased expression of BRAP mRNA
CTD PMID:31295307 NCBI chr12:111,642,146...111,686,023
Ensembl chr12:111,642,146...111,685,956
JBrowse link
G BRCA1 BRCA1 DNA repair associated decreases expression EXP glyphosate results in decreased expression of BRCA1 mRNA CTD PMID:31295307 NCBI chr17:43,044,295...43,125,364
Ensembl chr17:43,044,295...43,170,245
JBrowse link
G BRD1 bromodomain containing 1 increases expression ISO glyphosate results in increased expression of BRD1 mRNA CTD PMID:26302742 NCBI chr22:49,773,278...49,827,873
Ensembl chr22:49,773,283...49,827,512